featured
CDK4/6 Inhibitor–Based Therapy Improves Overall Survival in MBC Subgroups
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of the National Cancer Institute
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Overall Survival of CDK4/6-Inhibitors-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis
J. Natl. Cancer Inst 2020 May 14;[EPub Ahead of Print], F Schettini, F Giudici, M Giuliano, M Cristofanilli, G Arpino, L Del Mastro, F Puglisi, S De Placido, I Paris, P De Placido, S Venturini, M De Laurentis, P Conte, D Juric, A Llombart-Cussac, L Pusztai, A Prat, G Jerusalem, A Di Leo, D GeneraliFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.